finanzen.net
03.01.2019 18:25
Bewerten
(0)

Experimental Stem Cell Therapy Speeds Up Wound Healing in Diabetes

DRUCKEN

NEW YORK, Jan. 3, 2019 /PRNewswire/ -- The healing of wounded skin in diabetes can be sped up by more than 50 percent using injections of stem cells taken from bone marrow, a new study in mice shows.

(PRNewsfoto/NYU School of Medicine)

The research, led by scientists at NYU School of Medicine, focused on a chain of events in diabetes that makes skin sores more likely to form and less likely to heal.

Namely, the body's failure in diabetes to break down dietary sugar creates molecules called free radicals that can wreak havoc on cells and damage their DNA. These free radicals also trigger an inrush of immune cells and chemicals meant to fight infection that, researchers say, instead kill normal cells and cause diabetic skin ulcers. These wounds, they note, can take twice as long to heal as in healthy mammals and are prone to infection.  

Published in the January issue of the journal , the study showed that the injected stem cells restore a cell signaling pathway called Nrf2/Keap1, recently shown by the NYU team to be disrupted in diabetes. The rebalancing brought on by stem cell therapy, the researchers say, decreased wound healing time to 21 days in treated diabetic mice compared with 32 days in untreated diabetic mice. By contrast, normal mouse skin wounds usually heal in 14 days.

"Our study shows that in mice, stem-cell-based therapies can stimulate the Nrf2/Keap1 pathway to counteract inflammation and restore some of the skin's tissue-regenerating abilities impaired by diabetes," says senior study investigator and plastic surgeon an assistant professor in the Hansjörg Wyss Department of Plastic Surgery at NYU Langone Health.

The early-stage stem cells used in the current study are the kind that have the potential to mature into more than one kind of cell, but then specialize to serve within a particular mammalian organ like the skin. While essential to the formation of the body in the womb, pools of stem cells also persist in the adult body, where they can be triggered to serve as replacement parts when tissues are damaged, the goal of regenerative medicine.

Previous research by the NYU team had shown that in human diabetes, stem cells do not contribute normally to tissue regeneration. This led the team to test what injections of donated stem cells, known to deter an immune response, might do to correct the dysfunction.

Ceradini, director of research in plastic surgery at NYU Langone, says that if future experiments prove successful, his team's stem cell therapy could help in the healing not just of diabetic skin ulcers but also in repairing damage to diabetes-inflamed blood vessels.

The Centers for Disease Control and Prevention's latest figures show that more than 30 million Americans have diabetes, for which researchers estimate that one in 10 will develop some form of diabetic skin wound, typically a foot ulcer. Although rare, some of these can result in the need for amputation. Researchers have estimated the annual health care costs in the United States from skin wounds related to diabetes at more than $9 billion.

Study first author says "other than keeping wounds moist and covered," there are few treatment options for diabetic skin ulcers. She cautions that, although several labs have reduced the inflammation behind skin ulcers in early experiments, clinical trials using stem cells are still several years away. Rabbani, a research assistant professor at NYU Langone, says the research team next plans to develop an experimental stem-cell based therapy for testing in larger mammals.

Funding support for the study was provided by the American Diabetes Association Pathway Stop Diabetes Accelerator Award 1-16-ACE-08; National Institutes of Health grants P30 CA016087, S10 OD010584, and S10 OD018338; and New York State Stem Cell Science grant C026719.

Besides Ceradini and Rabbani, other researchers involved in these experiments, performed entirely at NYU Langone, are Marc Soares, MD; Sophia Hameedi, BA; Rohini Kadle, MD; Adnan Mubasher, MD; and Maria Kowzun, MD.

Media Inquiries:
DJ Haffeman
212-404-3567
 

Cision View original content to download multimedia:

SOURCE NYU Langone Health

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX fester -- Dow zurückhaltend gestartet -- US-Erstanträge auf 50-Jahrestief -- Gewinnmitnahmen bei Wirecard-Aktie -- Daimler wohl vor Jobaubbau -- Senvion, Deutsche Post, Pinterest, OSRAM im Fokus

Apple nimmt zweite Roboter-Linie zum iPhone-Recycling in Betrieb. PUMA-Aktionäre segnen Aktiensplit ab, wählen 2 AR-Mitglieder neu. Samsung nimmt Falt-Handy wegen möglicher Mängel unter die Lupe. Huawei bietet Deutschland 'No-Spy-Abkommen' an. Reifenhersteller-Aktien schwächer: Marktdaten von Michelin belasten Continental & Co. Lufthansa nimmt mit Schuldscheindarlehen 800 Millionen Euro auf. Goldman-Abstufung drückt Nordex-Aktie ins Minus.

Top-Rankings

KW 16: Analysten-Flops der Woche
Diese Aktien stehen auf den Verkauflisten der Experten
KW 16: Analysten-Tops der Woche
Diese Aktien stehen auf den Kauflisten der Experten
KW 15: Analysten-Flops der Woche
Diese Aktien stehen auf den Verkauflisten der Experten

Die 5 beliebtesten Top-Rankings

Die beliebtesten Arbeitgeber in Deutschland
Hier gibt es die beliebtesten Jobs
Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
DIe innovativsten Unternehmen
Diese Unternehmen sind am fortschrittlichsten
Das hat sich geändert
Diese Aktien hat George Soros im Depot
Diese Aktien hat Warren Buffett im Depot
Einige Änderungen unter den Top-Positionen
mehr Top Rankings

Umfrage

Wirtschaftsminister Peter Altmaier (CDU) sieht sich derzeit starker Kritik ausgesetzt. Zu Recht?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Standardwerte
15:12 Uhr
BMW ruft in USA Autos zurück
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Apple Inc.865985
TeslaA1CX3T
Netflix Inc.552484
Facebook Inc.A1JWVX
Alphabet A (ex Google)A14Y6F
Intel Corp.855681
TwitterA1W6XZ
GoProA1XE7G
Daimler AG710000
CommerzbankCBK100
Deutsche Bank AG514000
BASFBASF11
Volkswagen (VW) AG Vz.766403
BYD Co. Ltd.A0M4W9